Adma Biologics (ADMA) Current Assets (2011 - 2026)
Adma Biologics' (ADMA) quarterly Current Assets came in at $466.5 million in Q4 2025, up 40.77% YoY from $331.4 million in Q4 2024, and up 15.86% on a QoQ basis from $402.7 million in Q3 2025.
Adma Biologics (ADMA) Current Assets (2011 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 14 years of Current Assets data on file, last reported at $466.5 million in Q4 2025.
- Quarterly Current Assets rose 40.77% year-over-year to $466.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $466.5 million (up 40.77% YoY) and the FY2025 annual result came in at $466.5 million, up 40.77% from the prior year.
- Current Assets rose to $466.5 million in Q4 2025, from $402.7 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $466.5 million in Q4 2025 to a low of $171.4 million in Q2 2021.
- A 5-year average of $280.0 million and a median of $268.3 million in 2022 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2023 — Current Assets retreated 4.95% — and 2025, when it soared 40.77%.
- Tracing ADMA's Current Assets over 5 years: stood at $208.7 million in 2021, then rose by 29.55% to $270.4 million in 2022, then dropped by 4.95% to $257.0 million in 2023, then climbed by 28.95% to $331.4 million in 2024, then soared by 40.77% to $466.5 million in 2025.
- The last three Current Assets figures came in at $466.5 million (Q4 2025), $402.7 million (Q3 2025), and $399.6 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | 528.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 528.20 Mn |
| Dec 31, 2025 | 466.51 Mn |
| Sep 30, 2025 | 402.66 Mn |
| Jun 30, 2025 | 399.56 Mn |
| Mar 31, 2025 | 351.81 Mn |
| Dec 31, 2024 | 331.41 Mn |
| Sep 30, 2024 | 318.19 Mn |
| Jun 30, 2024 | 303.69 Mn |
| Mar 31, 2024 | 276.42 Mn |
| Dec 31, 2023 | 257.01 Mn |
| Sep 30, 2023 | 273.70 Mn |
| Jun 30, 2023 | 266.24 Mn |
| Mar 31, 2023 | 264.09 Mn |
| Dec 31, 2022 | 270.40 Mn |
| Sep 30, 2022 | 224.09 Mn |
| Jun 30, 2022 | 222.77 Mn |
| Mar 31, 2022 | 239.80 Mn |
| Dec 31, 2021 | 208.73 Mn |
| Sep 30, 2021 | 174.79 Mn |
| Jun 30, 2021 | 171.36 Mn |